Skip to main content
See every side of every news story
Published loading...Updated

FDA's Top Drug Regulator Resigns After Federal Officials Probe 'Serious Concerns'

  • Dr. George Tidmarsh, leading drug regulator at the U.S. Food and Drug Administration's Center for Drug Evaluation and Research , was placed on leave Friday after the Department of Health and Human Services Office of General Counsel was notified; he resigned Sunday.
  • Aurinia Pharmaceuticals sued, alleging Tidmarsh accepted bribes and defamed a former colleague during his FDA tenure and used his post to pursue a vendetta against Kevin Tang in U.S. District Court of Maryland.
  • Aurinia says Tidmarsh's LinkedIn post claiming voclosporin lacked proven benefit caused a 20% stock decline, wiping out over $350 million, and he later deleted it, saying it was in his personal capacity.
  • HHS said its Office of General Counsel was alerted, leading to Tidmarsh's leave, while the FDA's Center for Drug Evaluation and Research lost more than 1,000 staffers over the past year.
  • Tidmarsh's departure follows months of firings and departures at the FDA; the center he led, CDER, is the agency's largest division responsible for medicine review and safety.
Insights by Ground AI
Podcasts & Opinions

89 Articles

Newsbug.infoNewsbug.info
+14 Reposted by 14 other sources
Center

Top FDA Drug Chief Resigns While Under Investigation

Key Takeaways

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 60% of the sources are Center
60% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

The Washington Post broke the news in on Sunday, November 2, 2025.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal